AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24205043 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive telephone counseling intervention (monthly sessions by practice nurses over 12 months)
Number of subjects: 204
Study 24205043 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 204
Study 24205043 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive telephone counseling intervention
Number of subjects: 204
Study 22177466 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational messages attached to laboratory test reports targeting blood pressure control.
Number of subjects: 8690
Study 22177466 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational messages attached to laboratory test reports targeting foot inspection.
Number of subjects: 8690
Study 22177466 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational messages attached to laboratory test reports targeting glycaemic control.
Number of subjects: 8690
Study 22177466 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational messages attached to laboratory test reports targeting cholesterol control.
Number of subjects: 8690
Study 19890181 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for symptomatic lumbar disc herniation
Number of subjects: 0
Study 19890181 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression for spinal stenosis
Number of subjects: 0
Study 19890181 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression and fusion for degenerative spondylolisthesis
Number of subjects: 0
Study 19890181 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical care
Number of subjects: 0
Study 16728212 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering strategy
Number of subjects: 0
Study 16728212 — intervention group
Group type: COMPARATOR
Intervention: Moderate lipid-lowering strategy
Number of subjects: 0
Study 15199076 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin (6 mg/kg total body weight, administered intravenously over 30 minutes)
Number of subjects: 10
Study 15199076 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteer control group (matched by weight, age, and sex)
Number of subjects: 10
Study 15199076 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin in hepatic‐impaired patients
Number of subjects: 10
Study 11704596 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 22
Study 11704596 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 22
Study 9393380 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate zidovudine therapy
Number of subjects: 204
Study 9393380 — intervention group
Group type: COMPARATOR
Intervention: Deferred zidovudine therapy
Number of subjects: 204
Study 8260299 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 45
Study 8260299 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 45
Study 8260299 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 45
Study 8260299 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including diazepam, morphine, and no premedication)
Number of subjects: 45
Study 8260299 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpremedicated patients and those receiving diazepam
Number of subjects: 45
Study 2888507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (moderately intoxicating dose)
Number of subjects: 20
Study 2888507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30741725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation intervention in addition to a routine therapy program
Number of subjects: 40
Study 30741725 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy program
Number of subjects: 40
Study 28863595 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized stimulation and averaging (RSA)
Number of subjects: 3
Study 28863595 — intervention group
Group type: COMPARATOR
Intervention: Conventional averaging
Number of subjects: 3
Study 22918839 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug user stigma
Number of subjects: 340
Study 22918839 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger size of drug network
Number of subjects: 340
Study 22918839 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of heroin, cocaine, and crack
Number of subjects: 340
Study 22918839 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 340
Study 22918839 — intervention group
Group type: EXPERIMENTAL
Intervention: Homelessness in the past 6 months
Number of subjects: 340
Study 21459216 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fluocinolone acetonide insert (0.2 μg/day)
Number of subjects: 953
Study 21459216 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fluocinolone acetonide insert (0.5 μg/day)
Number of subjects: 953
Study 21459216 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 953
Study 21459216 — intervention group
Group type: EXPERIMENTAL
Intervention: Both low- and high-dose inserts
Number of subjects: 953
Study 19491822 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 12 mg
Number of subjects: 60
Study 19491822 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 4 mg
Number of subjects: 60
Study 19491822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16327334 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 600 mg/day
Number of subjects: 0
Study 16327334 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz 800 mg/day
Number of subjects: 0
Study 12631604 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 433
Study 12631604 — intervention group
Group type: COMPARATOR
Intervention: Control (no-TAM)
Number of subjects: 433
Study 10692608 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 40
Study 10692608 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 40
Study 9355816 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual treatment plus family treatment (education and training in communication and problem-solving skills)
Number of subjects: 52
Study 9355816 — intervention group
Group type: COMPARATOR
Intervention: Individual treatment
Number of subjects: 52
Study 8454476 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose rate brachytherapy (1000 cGy at 5 mm depth for three fractions)
Number of subjects: 342
Study 8454476 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose rate brachytherapy (1000 cGy at 10 mm depth for three fractions)
Number of subjects: 342
Study 8454476 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose rate brachytherapy (750 cGy at 10 mm depth for three fractions)
Number of subjects: 342
Study 8454476 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 342
Study 8454476 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 342
Study 8454476 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival from diagnosis and first treatment for curative
Number of subjects: 342
Study 8454476 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival from diagnosis and first treatment for palliative
Number of subjects: 342
Study 8454476 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival from diagnosis and first treatment for recurrent
Number of subjects: 342
Study 8454476 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 342
Study 3778567 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam with alcohol
Number of subjects: 12
Study 30530580 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based chronic pain self-management course (2.5-hour weekly sessions for 6 weeks)
Number of subjects: 121
Study 30530580 — intervention group
Group type: COMPARATOR
Intervention: Low-impact outdoor group physical activity (1-hour weekly sessions for 6 weeks)
Number of subjects: 121
Study 26818781 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 6202
Study 26818781 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 6202
Study 26818781 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran and Warfarin
Number of subjects: 6202
Study 25225209 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin levels in cases of preeclampsia
Number of subjects: 401
Study 25225209 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin levels in cases diagnosed before 37 weeks
Number of subjects: 401
Study 25225209 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin levels in cases diagnosed after 37 weeks
Number of subjects: 401
Study 25225209 — intervention group
Group type: COMPARATOR
Intervention: Copeptin levels in controls
Number of subjects: 401
Study 25225209 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin levels in gestational hypertension without proteinuria, gestational diabetes mellitus, or preterm birth
Number of subjects: 401
Study 21830863 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory questionnaires about a stressful event
Number of subjects: 263
Study 21830863 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 263
Study 20163785 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation-phase cognitive therapy (CT) for 8 months
Number of subjects: 84
Study 20163785 — intervention group
Group type: COMPARATOR
Intervention: Assessment control
Number of subjects: 84
Study 18855530 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg/day
Number of subjects: 630
Study 18855530 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensives)
Number of subjects: 630
Study 15738787 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to rest in bed
Number of subjects: 0
Study 15738787 — intervention group
Group type: COMPARATOR
Intervention: Advice to stay active
Number of subjects: 0
Study 12180580 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 1 microg/kg
Number of subjects: 80
Study 12180580 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 0.5 microg/kg and propofol 0.5 mg/kg
Number of subjects: 80
Study 12180580 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 1 microg/kg with propofol 0.5 mg/kg
Number of subjects: 80
Study 12180580 — intervention group
Group type: COMPARATOR
Intervention: saline 0.1 ml/kg
Number of subjects: 80
Study 12196747 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% topical minoxidil
Number of subjects: 393
Study 12196747 — intervention group
Group type: COMPARATOR
Intervention: 2% topical minoxidil
Number of subjects: 393
Study 12196747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study 9640368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam (5 mg)
Number of subjects: 10
Study 9640368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7864722 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 2.5 to 5 mg/day
Number of subjects: 3000
Study 7864722 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 32.5 to 35 mg/day
Number of subjects: 3000
Study 2532463 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 5.0 mg orally
Number of subjects: 8
Study 2532463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30467808 — intervention group
Group type: EXPERIMENTAL
Intervention: 300-mg bupivacaine (three INL-001 100-mg bupivacaine HCl collagen-matrix implants)
Number of subjects: 417
Study 30467808 — intervention group
Group type: COMPARATOR
Intervention: Placebo collagen-matrix implants
Number of subjects: 417
Study 28366698 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid avoidance
Number of subjects: 0
Study 28366698 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 26165398 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg daily, increasing to a maximum of 2500 mg)
Number of subjects: 449
Study 26165398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study 22739125 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (CIT)
Number of subjects: 20
Study 22739125 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Tryptophan Depletion (ATD)
Number of subjects: 20
Study 22739125 — intervention group
Group type: COMPARATOR
Intervention: Control (no pharmacological challenge)
Number of subjects: 20
Study 21563888 — intervention group
Group type: EXPERIMENTAL
Intervention: Disruptive TMS over PMv during PP + AO
Number of subjects: 0
Study 21563888 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS over frontal cortex during PP + AO
Number of subjects: 0
Study 21563888 — intervention group
Group type: EXPERIMENTAL
Intervention: Disruptive TMS over PMv during PP only
Number of subjects: 0
Study 21563888 — intervention group
Group type: COMPARATOR
Intervention: Disruptive TMS over frontal cortex during PP only
Number of subjects: 0
Study 18305997 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive video-assisted thyroidectomy (MIVAT)
Number of subjects: 0
Study 18305997 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgery
Number of subjects: 0
Study 16874171 — intervention group
Group type: EXPERIMENTAL
Intervention: MenC‐TT vaccine coadministered with DTaP‐HBV‐IPV/Hib
Number of subjects: 230
Study 16874171 — intervention group
Group type: COMPARATOR
Intervention: MenC‐CRM vaccine coadministered with DTaP‐HBV‐IPV/Hib
Number of subjects: 230
Study 12629566 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (regular dietary advice, weight loss stimulation, increased physical activity)
Number of subjects: 102
Study 12629566 — intervention group
Group type: COMPARATOR
Intervention: Control group (brief information about healthy diet and physical activity)
Number of subjects: 102
Study 11110850 — intervention group
Group type: EXPERIMENTAL
Intervention: TOS (20 g/d)
Number of subjects: 12
Study 11110850 — intervention group
Group type: COMPARATOR
Intervention: Reference treatment (sucrose)
Number of subjects: 12
Study 9168767 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone alone
Number of subjects: 291
Study 9168767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone with metronidazole
Number of subjects: 291
Study 9168767 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole, gentamicin, and ampicillin (triple-antibiotic group)
Number of subjects: 291
Study 8467026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia with propofol/alfentanil combined with nitrous oxide
Number of subjects: 25
Study 8467026 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 25
Study 29799077 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 229
Study 29799077 — intervention group
Group type: COMPARATOR
Intervention: No Digoxin
Number of subjects: 229
Study 27182031 — intervention group
Group type: EXPERIMENTAL
Intervention: IDeg flexible dosing (±8 h from an agreed dosing time)
Number of subjects: 458
Study 27182031 — intervention group
Group type: EXPERIMENTAL
Intervention: IDeg flexible dosing
Number of subjects: 458
Study 27182031 — intervention group
Group type: COMPARATOR
Intervention: IDeg fixed dosing (at the same time each day)
Number of subjects: 458
Study 24154700 — intervention group
Group type: EXPERIMENTAL
Intervention: palonosetron 0.075 mg i.v.
Number of subjects: 204
Study 24154700 — intervention group
Group type: COMPARATOR
Intervention: placebo (normal saline i.v.)
Number of subjects: 204
Study 22117892 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment using removable partial dentures
Number of subjects: 44
Study 22117892 — intervention group
Group type: EXPERIMENTAL
Intervention: Functionally orientated treatment based on the shortened dental arch
Number of subjects: 44
Study 22117892 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 44
Study 20179007 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) - loading dose of 140 mg/kg IV over 1 hour followed by 70 mg/kg IV every 4 hours for a total of 12 doses.
Number of subjects: 100
Study 20179007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18568325 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile oil of amomum (VOA) 0.5 mL, thrice per day
Number of subjects: 80
Study 18568325 — intervention group
Group type: COMPARATOR
Intervention: Western tertiary medicinal treatment
Number of subjects: 80
Study 15765452 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interscalene block
Number of subjects: 30
Study 15765452 — intervention group
Group type: COMPARATOR
Intervention: Continuous subacromial infusion
Number of subjects: 30
Study 15765452 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 12466507 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm-control group (serial cardioversions, antiarrhythmic drugs, oral anticoagulants)
Number of subjects: 522
Study 12466507 — intervention group
Group type: COMPARATOR
Intervention: Rate-control group (oral anticoagulants, rate-slowing medication)
Number of subjects: 522
Study 12466507 — intervention group
Group type: COMPARATOR
Intervention: Rate-control group
Number of subjects: 522
Study 12466507 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm-control group
Number of subjects: 522
Study 12466507 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 522
Study 10353071 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 91
Study 10353071 — intervention group
Group type: COMPARATOR
Intervention: Micronized fenofibrate 200 mg/day
Number of subjects: 91
Study 7864418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (0.75, 1.5, and 3 mg/70 kg)
Number of subjects: 12
Study 7864418 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (0.1 mg/70 kg; positive control)
Number of subjects: 12
Study 7864418 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 1936479 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-Metformin combination
Number of subjects: 100
Study 1936479 — intervention group
Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 100
Study 6179052 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg sulfinpyrazone
Number of subjects: 20
Study 6179052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31442695 — intervention group
Group type: EXPERIMENTAL
Intervention: Horror movie
Number of subjects: 20
Study 31442695 — intervention group
Group type: COMPARATOR
Intervention: Control movie
Number of subjects: 20
Study 30120131 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPP+ (dual antiplatelet therapy pretreatment)
Number of subjects: 790
Study 30120131 — intervention group
Group type: COMPARATOR
Intervention: DAPP- (no dual antiplatelet therapy pretreatment)
Number of subjects: 790
Study 27377542 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (7·5 g of 1% testosterone gel daily for 3 years)
Number of subjects: 308
Study 27377542 — intervention group
Group type: COMPARATOR
Intervention: Placebo (gel)
Number of subjects: 308
Study 25127170 — intervention group
Group type: EXPERIMENTAL
Intervention: Snack bars with 1.5 g β‐glucan
Number of subjects: 12
Study 25127170 — intervention group
Group type: EXPERIMENTAL
Intervention: Snack bars with 3 g β‐glucan
Number of subjects: 12
Study 25127170 — intervention group
Group type: EXPERIMENTAL
Intervention: Snack bars with 6 g β‐glucan
Number of subjects: 12
Study 25127170 — intervention group
Group type: COMPARATOR
Intervention: Control bars (0 g β‐glucan)
Number of subjects: 12
Study 25127170 — intervention group
Group type: COMPARATOR
Intervention: White bread controls
Number of subjects: 12
Study 22149921 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD alone
Number of subjects: 405
Study 22149921 — intervention group
Group type: COMPARATOR
Intervention: Subtotal nodal radiation therapy
Number of subjects: 405
Study 19234817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal magnesium sulfate 50 mg (3 ml)
Number of subjects: 60
Study 19234817 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free 0.9% NaCl (3 ml)
Number of subjects: 60
Study 17227906 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (20 mg/m2)
Number of subjects: 79
Study 17227906 — intervention group
Group type: COMPARATOR
Intervention: Liposomal daunorubicin (40 mg/m2)
Number of subjects: 79
Study 15111532 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg twice daily for 2 weeks)
Number of subjects: 30
Study 11673300 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA) alone
Number of subjects: 90
Study 11673300 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Local Anesthesia (LA)
Number of subjects: 90
Study 11673300 — intervention group
Group type: COMPARATOR
Intervention: Postoperative Local Anesthesia (LA)
Number of subjects: 90
Study 9647457 — intervention group
Group type: COMPARATOR
Intervention: Epidural injection with 8 ml of saline (Group 1)
Number of subjects: 53
Study 9647457 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural block with 8 ml of 1% mepivacaine (Group 2)
Number of subjects: 53
Study 9647457 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural block with a combination of 8 ml of 1% mepivacaine and 40 mg of methylprednisolone (Group 3)
Number of subjects: 53
Study 8207740 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril (2.5 mg daily)
Number of subjects: 31
Study 8207740 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine retard (20 mg twice daily)
Number of subjects: 31
Study 2913579 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 (2 msec on, 2 msec off) pulsed‐output ultrasound (3.0 MHz at 1.0 W/cm2)
Number of subjects: 10
Study 2913579 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous‐output ultrasound at 0.75, 1.5, and 3.0 MHz at 1.5 W/cm2
Number of subjects: 10
Study 2913579 — intervention group
Group type: COMPARATOR
Intervention: Control (0.0 W/cm2)
Number of subjects: 10
Study 2913579 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (benzydamine gel massaged with ultrasound applicator switched off)
Number of subjects: 10